ArticleArchives of gynecology and obstetrics2025
AXINEO: AXIllary response to NEOadjuvant chemotherapy for breast cancer: can we predict response based on a biomarker panel?
Article in Archives of gynecology and obstetrics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundUp to 60% of breast cancer patients achieve pathological complete response (pCR) and factors associated with breast pCR have been extensively investigated. In patients with initially node-positive disease predicting axillary response to treatment remains challenging. Our study examines a biomarker panel assessed on core-biopsy lymph-node metastatic tissue with the goal to establish predictive markers for nodal positive breast cancer. MATERIALS AND
methodsForty women with core biopsy-proven node-positive breast cancer scheduled to receive neoadjuvant treatment at the certified Breast Cancer Center of the University Hospital Schleswig-Holstein Campus Lübeck were included. The expressions of CAIX, PD-L1, TROP2, MSH2, MSH6, MLH1, and PMS2 as well as p53 mutation were assessed. Biomarkers were chosen based on their association with tumorigenesis and tumor progression. Statistical analysis was performed using SPSS 29. This investigator-initiated study was supported by a research grant from Gilead (Gilead Förderprogramm).
resultsHigher CAIX levels were associated with triple-negative and Her2-positive receptor status (p = 0.003), Ki67 ≥ 50% in breast core biopsy (p = 0.005), as well as postmenopausal status (p = 0.007). P53 mutation was more frequent in G3 tumors (p = 0.025). All lymph-node metastases were microsatellite stable (MSS). None of the markers could significantly predict pathological response (complete, breast, or nodal).
conclusionOur study shows upregulated CAIX in lymph-node metastasis frequently occurs in aggressive and highly proliferative tumors. However, none of the examined biomarkers could predict nodal response to therapy. Further research is necessary to better identify patients most likely to achieve nodal response through neoadjuvant chemotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.